Cyclacel Pharmaceuticals Inc (CYCC)
1.60
-0.70
(-30.43%)
USD |
NASDAQ |
Apr 25, 16:00
1.51
-0.09
(-5.62%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Net Income (Quarterly): -5.271M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.271M |
| September 30, 2023 | -6.032M |
| June 30, 2023 | -5.448M |
| March 31, 2023 | -5.804M |
| December 31, 2022 | -7.419M |
| September 30, 2022 | -5.096M |
| June 30, 2022 | -4.575M |
| March 31, 2022 | -4.108M |
| December 31, 2021 | -4.864M |
| September 30, 2021 | -4.987M |
| June 30, 2021 | -5.127M |
| March 31, 2021 | -3.478M |
| December 31, 2020 | -2.804M |
| September 30, 2020 | -2.256M |
| June 30, 2020 | -2.166M |
| March 31, 2020 | -1.22M |
| December 31, 2019 | -2.305M |
| September 30, 2019 | -1.901M |
| June 30, 2019 | -1.783M |
| March 31, 2019 | -1.842M |
| December 31, 2018 | -2.018M |
| September 30, 2018 | -2.068M |
| June 30, 2018 | -1.852M |
| March 31, 2018 | -1.349M |
| December 31, 2017 | -1.871M |
| Date | Value |
|---|---|
| September 30, 2017 | -1.857M |
| June 30, 2017 | -2.187M |
| March 31, 2017 | -1.555M |
| December 31, 2016 | -2.839M |
| September 30, 2016 | -2.946M |
| June 30, 2016 | -2.965M |
| March 31, 2016 | -3.041M |
| December 31, 2015 | -3.374M |
| September 30, 2015 | -2.709M |
| June 30, 2015 | -3.347M |
| March 31, 2015 | -4.912M |
| December 31, 2014 | -4.799M |
| September 30, 2014 | -4.907M |
| June 30, 2014 | -4.812M |
| March 31, 2014 | -4.869M |
| December 31, 2013 | -3.559M |
| September 30, 2013 | -5.004M |
| June 30, 2013 | 1.492M |
| March 31, 2013 | -3.082M |
| December 31, 2012 | -4.764M |
| September 30, 2012 | -1.89M |
| June 30, 2012 | -3.577M |
| March 31, 2012 | -2.955M |
| December 31, 2011 | -3.658M |
| September 30, 2011 | -3.445M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-7.419M
Minimum
Dec 2022
-1.22M
Maximum
Mar 2020
-4.034M
Average
-4.575M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Corvus Pharmaceuticals Inc | -6.653M |
| Oragenics Inc | -12.75M |
| Relmada Therapeutics Inc | -25.17M |
| Alpine Immune Sciences Inc | 5.96M |
| MAIA Biotechnology Inc | -6.257M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.031M |
| Total Expenses (Quarterly) | 5.391M |
| EPS Diluted (Quarterly) | -5.90 |
| Enterprise Value | -1.269M |
| Profit Margin (Quarterly) | -17.00K% |
| Earnings Yield | -1.67K% |
| Normalized Earnings Yield | -1645.18 |